Close Menu

NEW YORK – Inflammatix on Friday announced that it had raised $32 million in Series C financing to advance its rapid HostDx tests through commercial launch in Europe and submission for clearance to the US Food and Drug Administration in 2021.

The funding round included participation from existing investors Khosla Ventures, Northpond Ventures, and Think.Health Ventures, and new investors that included Grey Sky Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.